Finance

Lists
VRDN:NASDAQ
Viridian Therapeutics Inc
$30.87
+1.28%
(+0.39) 1D
Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VRDN...
Open
$30.24
High
$30.96
Low
$29.81
Mkt. cap
3.51B
Avg. vol.
2.69M
Volume
1.20M
52-wk high
$34.29
52-wk low
$13.19
EPS
-$4.37
Beta
1.07
Shares outstanding
113.56M
No. of employees
252
Open
$30.24
High
$30.96
Low
$29.81
Mkt. cap
3.51B
Avg. vol.
2.69M
Volume
1.20M
52-wk high
$34.29
52-wk low
$13.19
EPS
-$4.37
Beta
1.07
Shares outstanding
113.56M
No. of employees
252
News stories
From web sources and news partners
About Viridian Therapeutics Inc
CEO-
Employees252
Founded2010
HeadquartersWaltham, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Websiteviridiantherapeutics.com
Analyst ratings
Based on 9 analysts giving stock ratings to VRDN in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for VRDN in the last 3 months.
Highest
Current $30.87
$54.00 (+74.93%)
Average
$42.13 (+36.48%)
Lowest
$33.00 (+6.90%)
Analyst
Recommendation
Action
Price target
Projected
Date
Derek Archila
Wells Fargo
Buy
Reiterated
$39.00
+26.3%
11/09/2026
Douglas Tsao
H.C. Wainwright
Buy
Maintained
$40.00
+29.6%
11/09/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
$54.00
+74.9%
11/05/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Maintained
$33.00
+6.9%
11/05/2026
Lisa Walter
RBC Capital
Buy
Reiterated
$41.00
+32.8%
11/05/2026
Richard Law CFA
Goldman Sachs
Buy
Maintained
$53.00
+71.7%
11/04/2026
Laura Chico
Wedbush
Buy
Maintained
$42.00
+36.1%
11/05/2026
Rami Katkhuda
LifeSci Capital
Buy
Maintained
$35.00
+13.4%
10/02/2026
Gregory Renza
Truist Financial
Buy
Maintained
-
-
09/01/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$40.00
+29.6%
08/13/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
08/06/2026
Lachlan Hanbury Brown
William Blair
Buy
Maintained
-
-
08/06/2026
Serge Belanger
Needham
Buy
Maintained
$34.00
+10.1%
08/06/2026
Faisal Khurshid
Jefferies
Buy
Maintained
$30.00
-2.8%
06/30/2026
Thomas Smith
Leerink Partners
Buy
Reiterated
$50.00
+62%
04/06/2026
Maneka Mirchandaney
Evercore ISI
Buy
Maintained
$32.00
+3.7%
04/02/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
132.00K
141.00K
284.00K
25.75M
Cost of goods sold
92.71M
77.63M
71.58M
71.62M
Cost of revenue
92.71M
77.63M
71.58M
71.62M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
33.67M
38.68M
54.98M
57.61M
Operating expense
33.67M
38.68M
54.98M
57.61M
Total operating expenses
126.38M
116.31M
126.55M
129.23M
Operating income
-126.25M
-116.17M
-126.27M
-103.48M
Other non operating income
-2.12M
6.86M
-1.03M
2.00M
EBT including unusual items
-120.36M
-104.90M
-127.12M
-101.21M
EBT excluding unusual items
-123.86M
-104.90M
-127.12M
-101.21M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-120.36M
-104.90M
-127.12M
-101.21M
Net profit margin
-91,178.03%
-74,397.87%
-44,760.21%
-393.01%
Earnings per share
-1.08
-0.90
-1.05
-0.81
Interest and investment income
7.79M
7.87M
8.49M
9.54M
Interest expense
-3.28M
-3.46M
-8.31M
-9.27M
Net interest expenses
4.51M
4.41M
183.00K
264.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-126.13M
-116.05M
-126.15M
-103.13M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps